Heidi Ko: How molecular classification impacts targeted therapy options

Heidi Ko, Medical Director, Medical Affairs at Labcorp Drug Development, shared a post on LinkedIn:

“Uterine cancer is the most common gynecologic cancer in the U.S., with increasing incidence and mortality rate. This Molecular Tumor Board case presented is about a 56-year-old female patient with uterine cancer and an underlying POLE V411L alteration. Join us as we discuss molecular subgroups in uterine cancer and how molecular classification impacts targeted therapy options.”

Read further.
Source: Heidi Ko/LinkedIn